CNS Pharmaceuticals Stock (NASDAQ:CNSP)

Forecast Ownership Financials Chart

Previous Close

$1.34

52W Range

$0.99 - $800.00

50D Avg

$2.98

200D Avg

$11.64

Market Cap

$3.77M

Avg Vol (3M)

$537.83K

Beta

1.08

Div Yield

CNSP Company Profile

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Nov 08, 2019

Website

CNSP Performance

CNSP Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-14.90M	$-18.87M	$-15.27M
Net Income	$-14.86M	$-18.85M	$-15.27M
EBITDA	$-14.90M	$-18.86M	$-15.26M
Basic EPS	$-38.87	$-251.35	$-560.83
Diluted EPS	$-38.87	$-250.19	$-560.83

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q4 19Mar 12, 20 | 4:30 PM

Peer Comparison

Ticker	Company
HEPA	Hepion Pharmaceuticals, Inc.
OCEA	Ocean Biomedical, Inc.
ZVSA	ZyVersa Therapeutics, Inc.
IMMX	Immix Biopharma, Inc.
SONN	Sonnet BioTherapeutics Holdings, Inc.
ELEV	Elevation Oncology, Inc.
ENVB	Enveric Biosciences, Inc.